Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
The past 2 decades have seen a revolution in our approach to therapeutic immunosuppression. We have moved from relying on broadly active traditional medications, such as prednisolone or methotrexate, toward more specific agents that often target a single receptor, cytokine, or cell type, using monoclonal antibodies, fusion proteins, or targeted small molecules. This change has transformed the treatment of many conditions, including rheumatoid arthritis, cancers, asthma, and inflammatory bowel disease, but along with the benefits have come risks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Hynes (2002) · doi:10.1016/s0092-8674(02)00971-6 · Cited by 8,606
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Terrault, N. A., Lok, A. S. F., McMahon, B. J., Chang, K., Hwang, J. P., Jonas, M. M., Brown, R. S., Bzowej, N. H., & Wong, J. B. (2018) · Hepatology · doi:10.1002/hep.29800 · Cited by 4,306
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381 · cited 3×
“Data from two randomized controlled trials performed in ALK-positive, treatmentnaive and previously treated patients (1115, 1117) did not reveal evidence for an increased rate of infections associated with the use of crizotinib, although neutropenia occurred in 11 to 13% of patients.”
BackgroundResultFirst-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527 · cited 2×
“Infective complications have not been reported in clinical trials of ceritinib, alectinib, or brigatinib (1111, 1123, 1124), although 20% of patients on both crizotinib and alectinib developed nasopharyngitis in a Japanese study (1125).”
BackgroundRole of the gut microbiota in nutrition and health
Valdes, A. M., Walter, J., Segal, E., & Spector, T. D. (2018) · BMJ · doi:10.1136/bmj.k2179 · Cited by 2,375
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103 · cited 1×
“The gain-offunction JAK2 V617F mutation, leading to increased signal transduction and activator of transcription STAT-3 and STAT-5 activity, is present in more than 95% of patients with PCRV and in 50 to 60% of patients with myelofibrosis (930, 931).”
BackgroundTNF-mediated inflammatory disease
Bradley, Jr. (2008) · The Journal of Pathology · doi:10.1002/path.2287 · Cited by 2,094 · cited 1×
“TNF- is produced by macrophages and T lymphocytes as a 233-amino-acid transmembrane precursor protein (35).”
BackgroundOcrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1601277 · Cited by 2,021 · cited 1×
“The OPERA I and OPERA II trial results were published in 2017, comparing ocrelizumab to interferon beta-1 in relapsing MS (499).”
ResultCluster analysis and clinical asthma phenotypes
Haldar, P., Pavord, I. D., Shaw, D. E., Berry, M. A., Thomas, M., Brightling, C. E., Wardlaw, A. J., & Green, R. H. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200711-1754oc · Cited by 1,987
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964 · cited 7×
“ALK rearrangements are seen in 3 to 5% of non-small cell lung cancers (NSCLC), most commonly in adenocarcinomas (1104).”
BackgroundInfluentialIgE and mast cells in allergic disease
Galli, S. J., & Tsai, M. (2012) · Nature Medicine · doi:10.1038/nm.2755 · Cited by 1,799 · cited 1×
“Mast cells and basophils are key drivers of not only acute asthma episodes and CIU but also the chronic pulmonary changes and remodeling that occur in asthma (674).”
BackgroundPfeffer, K., Matsuyama, T., Kündig, T. M., Wakeham, A., Kishihara, K., Shahinian, A., Wiegmann, K., Ohashi, P. S., Krönke, M., & Mak, T. W. (1993) · Cell · doi:10.1016/0092-8674(93)90134-c · Cited by 1,677
The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing
Gaffen, S. L., Jain, R., Garg, A. V., & Cua, D. J. (2014) · Nature reviews. Immunology · doi:10.1038/nri3707 · Cited by 1,585
Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301668 · Cited by 1,547
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445 · cited 1×
“In the POLLUX trial, 569 patients with previously treated multiple myeloma were randomized to daratumumab, dexamethasone, and lenalidomide or dexamethasone and lenalidomide alone (569).”
MethodPerforin and granzymes: function, dysfunction and human pathology
Voskoboinik, I., Whisstock, J. C., & Trapani, J. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3839 · Cited by 1,327
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322 · cited 1×
“The only phase III trial of elotuzumab was ELOQUENT-2 (575), in which 646 patients with refractory multiple myeloma were randomized to receive elotuzumab, lenalidomide, and dexamethasone or lenalidomide and dexamethasone alone.”
BackgroundCohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61769-3 · Cited by 1,205 · cited 2×
“High rates of herpes simplex virus and herpes zoster infections were seen in the CAMMS223, CARE-MS I, and CARE-MS II trials (526, 543, 544).”
BackgroundSoria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D., Yu, C.-J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30123-x · Cited by 1,151 · cited 1×
“Infective complications have not been reported in clinical trials of ceritinib, alectinib, or brigatinib (1111, 1123, 1124), although 20% of patients on both crizotinib and alectinib developed nasopharyngitis in a Japanese study (1125).”
BackgroundWenzel, S., Castro, M., Corren, J., Maspero, J., Wang, L., Zhang, B., Pirozzi, G., Sutherland, E. R., Evans, R. R., Joish, V. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30307-5 · Cited by 985
Derosa, L., Hellmann, M. D., Spaziano, M., Halpenny, D., Fidelle, M., Rizvi, H., Long, N., Plodkowski, A. J., Arbour, K. C., Chaft, J. E., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy103 · Cited by 908 · cited 1×
“decreased efficacy of ICI therapy, for example, in kidney cancer (1191), non-small cell”
BackgroundRuxolitinib versus standard therapy for the treatment of polycythemia vera
Vannucchi, A. M., Kiladjian, J. J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C. N., Pane, F., Zachee, P., Mesa, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409002 · Cited by 891
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810787 · Cited by 869
Genovese, M. C., McKay, J. D., Nasonov, E. L., Mysler, E. F., da Silva, N. A., Alecock, E., Woodworth, T., & Gomez‐Reino, J. J. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23940 · Cited by 855 · cited 2×
“tocilizumab is effective in reducing the activity of RA (764, 765).”
BackgroundBachert, C., Mannent, L., Naclerio, R. M., Mullol, J., Ferguson, B. J., Gevaert, P., Hellings, P., Jiao, L., Wang, L., Evans, R. R., et al. (2016) · JAMA · doi:10.1001/jama.2015.19330 · Cited by 794
The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aar6918 · Cited by 777
Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kantarjian, H., Shah, N. P., Bixby, D., Mauro, M. J., Flinn, I., O'Hare, T., Hu, S., Narasimhan, N. I., Rivera, V. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205127 · Cited by 769 · cited 2×
“Ponatinib is a TKI active against both unmutated and mutated BCR-ABL and, hence, can be active against disease resistant to other BCR-ABL tyrosine kinase inhibitors (1025).”
BackgroundCree, B. A. C., Bennett, J. L., Kim, H. J., Weinshenker, B. G., Pittock, S. J., Wingerchuk, D. M., Fujihara, K., Paul, F., Cutter, G. R., Marignier, R., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31817-3 · Cited by 756
Cohen, S., Hurd, E., Cush, J., Schiff, M., Weinblatt, M. E., Moreland, L. W., Kremer, J., Bear, M. B., Rich, W. J., & McCabe, D. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10141 · Cited by 638
Ito, H., Takazoe, M., Fukuda, Y., Hibi, T., Kusugami, K., Andoh, A., Matsumoto, T., Yamamura, T., Azuma, J., & Nishimoto, N. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.012 · Cited by 636
Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Hartmann, J., Haap, M., Kopp, H.-G., & Lipp, H.-P. (2009) · Current Drug Metabolism · doi:10.2174/138920009788897975 · Cited by 630
Hoffman, H. M., Throne, M. L., Amar, N. J., Sebai, M., Kivitz, A. J., Kavanaugh, A., Weinstein, S. P., Belomestnov, P., Yancopoulos, G. D., Stahl, N., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23687 · Cited by 577
Cutting Edge: Interleukin 17 Signals through a Heteromeric Receptor Complex
Toy, D., Kugler, D., Wolfson, M., Bos, T. V., Gurgel, J., Derry, J., Tocker, J., & Peschon, J. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.36 · Cited by 570
The structural basis of antibody–antigen recognition
Sela-Culang, I., Kunik, V., & Ofran, Y. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00302 · Cited by 530
Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., Riely, G. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00614-2 · Cited by 471
Wang, M., Rule, S., Zinzani, P. L., Goy, A., Casasnovas, O., Smith, S. D., Damaj, G., Doorduijn, J., Lamy, T., Morschhauser, F., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33108-2 · Cited by 453
Feagan, B. G., Sandborn, W. J., D'Haens, G., Panés, J., Kaser, A., Ferrante, M., Louis, E., Franchimont, D., Dewit, O., Seidler, U., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30570-6 · Cited by 451
Targan, S. R., Feagan, B., Vermeire, S., Panaccione, R., Melmed, G. Y., Landers, C., Li, D., Russell, C., Newmark, R., Zhang, N., et al. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.298 · Cited by 383
Kuehr, J., Brauburger, J., Zielen, S., Schauer, U., Kamin, W., Von Berg, A., Leupold, W., Bergmann, K.-C., Rolinck-Werninghaus, C., Gräve, M., et al. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.121949 · Cited by 342
Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab
Marsh, R. A., Allen, C. E., McClain, K. L., Weinstein, J. L., Kanter, J., Skiles, J., Lee, N. D., Khan, S. P., Lawrence, J., Mo, J. Q., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24188 · Cited by 310 · cited 1×
“Off-label use includes B cell chronic lymphocytic leukemia (527), T cell promyelocytic leukemia (528), Sézary syndrome (529), refractory autoimmune cytopenia (530, 531), acute graft-verse-host disease (532), hemophagocytic lymphohistiocytosis (533), and solid organ transplantation (276, 534, 535).”
BackgroundDamato, V., Evoli, A., & Iorio, R. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.1637 · Cited by 290 · cited 1×
“Off-label use in autoimmune disease includes multiple sclerosis (360, 361), thrombotic thrombocytopenic purpura (362, 363), immune thrombocytopenia (ITP) (364), myasthenia gravis (365), neuromyelitis optica (366), lupus nephritis (367), idiopathic membranous nephropathy (368), autoimmune hemolytic anemia (369), and ch…”
BackgroundSerious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer
Varughese, T., Taur, Y., Cohen, N., Palomba, M. L., Seo, S. K., Hohl, T. M., & Redelman-Sidi, G. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy175 · Cited by 271
Chamilos, G., Lionakis, M. S., & Kontoyiannis, D. P. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix687 · Cited by 267
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
Hantschel, O., Rix, U., & Superti-Furga, G. (2008) · Leukemia & Lymphoma · doi:10.1080/10428190801896103 · Cited by 256 · cited 22×
“BTK is also involved in chemokine-mediated homing and adhesion of chronic lymphocytic leukemia (CLL) cells to the microenvironment, contributing to their maintenance and proliferation (947).”
BackgroundInfluentialLippitz, B. E., & Harris, R. A. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1093722 · Cited by 248 · cited 1×
“marker in sepsis (755), malignancy (756), and several other conditions (752, 757, 758).”
BackgroundSpigel, D. R., Reynolds, C., Waterhouse, D., Garon, E. B., Chandler, J., Babu, S., Thurmes, P., Spira, A., Jotte, R., Zhu, J., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.02.022 · Cited by 229 · cited 1×
“In addition, recent studies have begun to combine ALK inhibitors with other agents, including immune checkpoint inhibitors (1126), and the infectious complications resulting from this are at present undefined.”
BackgroundElkrief, A., El Raichani, L., Richard, C., Messaoudene, M., Belkaid, W., Malo, J., Belanger, K., Miller, W., Jamal, R., Letarte, N., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1568812 · Cited by 208 · cited 1×
“lung cancer (1192, 1193), and metastatic melanoma (1194), and in cancers more”
BackgroundBlanco, F. J., Möricke, R., Dokoupilova, E., Codding, C., Neal, J., Andersson, M., Rohrer, S., & Richards, H. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40070 · Cited by 185
Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials
Lebwohl, M. G., Papp, K. A., Marangell, L. B., Koo, J., Blauvelt, A., Gooderham, M., Wu, J. J., Rastogi, S., Harris, S., Pillai, R., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.08.024 · Cited by 179
Strategies targeting the IL-4/IL-13 axes in disease
May, R. D., & Fung, M. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.018 · Cited by 166
To B or not to B: B cells and the Th2-type immune response to helminths
Harris, N., & Gause, W. C. (2011) · Trends in Immunology · doi:10.1016/j.it.2010.11.005 · Cited by 166
Fully human therapeutic monoclonal antibodies.
Weiner, L. M. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000192105.24583.83 · Cited by 164
(2014) · The Lancet · doi:10.1016/s0140-6736(14)61095-3 · Cited by 149 · cited 1×
“Off-label use includes B cell chronic lymphocytic leukemia (527), T cell promyelocytic leukemia (528), Sézary syndrome (529), refractory autoimmune cytopenia (530, 531), acute graft-verse-host disease (532), hemophagocytic lymphohistiocytosis (533), and solid organ transplantation (276, 534, 535).”
BackgroundA systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)
Rathbone, J., Kaltenthaler, E., Richards, A., Tappenden, P., Bessey, A., & Cantrell, A. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-003573 · Cited by 110 · cited 1×
“hemolytic uremic syndrome (aHUS) (1203), which is caused by mutations in regulatory”
BackgroundCD4 + T Cells: Guardians of the Phagosome
Tubo, N. J., & Jenkins, M. K. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00097-13 · Cited by 105
Cheung, C. C., Constantine, M., Ahmadi, A., Shiau, C., & Chen, L. Y. C. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.04.002 · Cited by 78
Cited by
Accelerating antibiotic discovery through artificial intelligence
Melo, M. C. R., Maasch, J. R. M. A., & de la Fuente-Nunez, C. (2021) · Communications Biology · doi:10.1038/s42003-021-02586-0 · Cited by 234
Metadata
- Authors
- Davis, J. S., Ferreira, D., Paige, E., Gedye, C., & Boyle, M.
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 2020-06-17
- Volume
- 33
- Issue
- 3
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- OpenAlex
- W3033539211
- Cited by
- 187
- References
- 63
- FWCI
- 5.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.